[Gadolinium deposition-"gadolinium deposition disease"]

Area of Science:

• Radiology
• Toxicology
• Medical Imaging

Background:

• Gadolinium (Gd)-based contrast agents (GBCAs) have been standard in diagnostic MRI since 1988.
• Initially considered safe at approved doses, concerns arose due to Gd-associated disorders like nephrogenic systemic fibrosis and adverse reactions.
• Recent literature highlights Gd retention in the brain and bone, prompting re-evaluation.

Purpose of the Study:

• To review the evolving understanding of Gadolinium deposition from contrast agents.
• To address the clinical significance of observed Gd retention in the human body.
• To contextualize patient-reported symptoms in relation to established medical evidence.

Main Methods:

• Literature review of studies on Gadolinium deposition and associated health effects.
• Analysis of clinical data regarding adverse events and patient-reported symptoms.
• Examination of regulatory actions and scientific discourse surrounding GBCAs.

Main Results:

• Gadolinium deposition in various tissues, including the brain and bone, has been documented.
• Despite deposition, no direct clinical evidence links GBCAs to patient symptoms or health issues.
• Patient advocacy groups have coined "gadolinium deposition disease" for reported symptom complexes.

Conclusions:

• While Gadolinium deposition is a known phenomenon, its clinical impact remains unproven.
• Current evidence does not support a causal link between Gd retention and patient-reported disorders.
• Further research is needed to fully understand the long-term implications of Gadolinium deposition.